Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism

Yuanyuan Sun1, Xingguo Zhang2, Hua Gao3

  • 1Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250000, Shandong, China.

Insights

MicroRNAs (miRNAs) show potential as biomarkers for pulmonary thromboembolism (PTE) progression. Specifically, hsa-miR-514a-5p exacerbates PTE by targeting CHRDL1, worsening lung injury and right ventricular hypertrophy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Pulmonary thromboembolism (PTE) diagnosis is challenging.
  • MicroRNAs (miRNAs) are emerging biomarkers, but their role in PTE is unclear.

Purpose of the Study:

  • To identify potential miRNA biomarkers for PTE progression.
  • To investigate the role of hsa-miR-514a-5p in PTE pathogenesis.

Main Methods:

  • miRNA microarray analysis to compare intermediate-risk and low-risk PTE groups.
  • In vivo rat model of PTE to assess the effects of miR-514a-5p.
  • Histological analysis of lung and right ventricular tissues.
  • Measurement of right ventricular hypertrophy index (RVHI) and cardiac biomarkers (BNP, NT-pro-BNP).

Main Results:

  • 83 miRNAs exhibited altered expression in intermediate-risk PTE.
  • hsa-miR-514a-5p was identified as a potential PTE progression biomarker.
  • Overexpression of miR-514a-5p in a rat PTE model worsened lung and right ventricular pathology, increased RVHI, and elevated BNP/NT-pro-BNP levels.
  • miR-514a-5p possibly exerts its effects by downregulating CHRDL1 expression.

Conclusions:

  • hsa-miR-514a-5p exacerbates PTE development by promoting inflammation, lung injury, and right ventricular hypertrophy.
  • Targeting CHRDL1 by miR-514a-5p is a potential mechanism driving PTE progression.
  • miR-514a-5p warrants further investigation as a therapeutic target and diagnostic biomarker for PTE.